Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Molecular Approaches to Diagnosing and Managing Infectious Diseases: Practicality and Costs
Table 1
FDA-approved molecular diagnostic tests for infectious diseasea
Test | Method | Companyb |
---|---|---|
Chlamydia trachomatis detection | PCRc LCR TMA Hybrid capture | Roche Abbott Gen-Probe Digene |
Neisseria gonorrhoeae detection | LCR Hybrid capture | Abbott Digene |
C. trachomatis/N. gonorrhoeae screening/detection | Hybridization SDR | Gen-Probe Becton-Dickinson |
Mycobacterium tuberculosis detection | PCR TMA | Roche Gen-Probe |
HPV screening | Hybrid capture | Digene |
CMV | Hybrid capture NASBA | Digene Organon Teknika |
Grp A strep detection | Hybridization | Gen-Probe |
HIV quantitation | PCR | Roche |
Gardnerella, T. vaginalis, and Candida | Hybridization | Becton-Dickinson |
Culture confirmation for bacteria and fungi | Hybridization | Gen-Probe |
aThe table contains examples of commercially available methods and is not intended to be all-inclusive. Websites of the principle manufacturers are a useful source of the most up-to-date information.
bCompanies: Digene, Silver Spring, MD; Chiron, Emeryville, CA; Roche, Branchburg, NJ; Organon Teknika, Durham, NC; Murex/Abbott, Abbott Park, IL; Gen-Probe, San Diego, CA; Abbott, Abbott Park, IL; Becton-Dickinson, Cockeysville, MD.
cPCR = polymerase chain reaction; LCR = ligase chain reaction; TMA = transcription-mediated amplification; SDR = strand displacement reaction; NASBA = nucleic acid strand-based amplification.